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A B S T R A C T
The use of biologic mesh, which is considered resistant to infection, has become common. It is
preferred over synthetic mesh for use in contaminated ﬁelds. Fungal infection with inﬁltration of
biologic mesh is rare and has not been reported. In this paper, we report a case of a patient who
underwent multiple laparotomies and received multiple antibiotics and an azole antifungal. Biologic
mesh was used, but it ultimately required removal because of chronic infection with Candida krusei.
On biopsy, the yeast was found to have inﬁltrated the mesh.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Repair of abdominal wall hernias with mesh has become
common since it was ﬁrst introduced in the 1950s [1]. The main
beneﬁt of using mesh is reduced recurrence of the hernia [2,3].
Various artiﬁcial mesh materials, both absorbable and non-
absorbable, have been associated with a small but signiﬁcant
infection risk [4]. Biologic mesh was recently introduced. Its
advantage is that it can be used to close abdominal wall defects in
contaminated or infected ﬁelds [5]. In this paper, we report a case
of infection of a biologic mesh following repair of abdominal wall
hernia. Candida krusei was repeatedly isolated despite administra-
tion of antifungals. We also discuss the literature regarding the
optimal treatment for this case.
Case report
The patient is a 40-year-old male who presented on March
15th, 2011 with a strangulated epigastric hernia. The hernia had
been present for six years and was increasing in size, but the
patient did not seek immediate medical care. Comorbidities
included morbid obesity (BMI = 45), diabetes, and nicotine
abuse. He underwent emergency operation, in which small
bowel resection and hernia repair were performed. The patient
clinically deteriorated and was returned to the OR four days
later, during which he underwent colectomy for dead bowel and* Corresponding author. Tel.: +1 2487605812.
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3.0/).fascial debridement of the abdominal wall for necrotizing
fasciitis. The patient developed sepsis, respiratory distress,
and acute renal injury. Cultures obtained intraoperatively
showed polymicrobial ﬂora, including Gr. B Streptococcus,
Clostridium perfringens, Prevotella spp., Enterobacter spp., and
Candida albicans. Management with antibiotics was started
with meropenem, clindmycin, and ﬂuconazole. The latter was
given for 10 days and then extended for 10 more days
because new wound cultures grew C. albicans. The abdominal
fascia was left open, and a vacuum-assisted closure device was
used. The patient had a planned return to the OR two days
later during which more fascia was debrided, and another small
bowel resection was performed for more necrotic bowel.
Ileostomy was performed. Twenty days after admission, he
was returned to the OR for an anastomotic leak. Twenty-four
days after admission, the patient again went to the OR for
tracheostomy, further abdominal wall debridement, and place-
ment of non-crosslinked human dermic mesh (Allomax-Bard).
The antibiotics, including ﬂuconazole, were continued. The
patient returned to the OR 48 h later for re-exploration,
irrigation, and removal and replacement of the mesh. On
subsequent cultures, yeast organisms were seen on the Gram
stain of the wound. Fluconazole was discontinued, and the
patient was started on micafungin 100 mg daily. Micafungin
was kept for 2 weeks. The patient later underwent skin closure
over the mesh with closed suction drainage. He made a slow
recovery over the next six weeks but was left with a chronically
draining wound from which C. krusei grew on repeated cultures
for a period of two months despite two consecutive coursese under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. The axial image obtained as part of a CT of the abdomen and pelvis performed
without contrast demonstrated a linear area of increased density (dashed arrow)
corresponding to the hernia mesh at the anterior aspect of the peritoneal cavity
ﬁlling the anterior facial defect with ﬂuid both superﬁcial and deep to this mesh
(solid arrows).
Fig. 2. A photomicrograph showing budding yeast and pseudohyphae consistent
with Candida spieces and inﬂammatory debris within the mesh. (Silver
methenamine stain, original magniﬁcation 400.)
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abdomen showed a large ﬂuid collection between the skin and
the mesh (Fig. 1). The patient then underwent mesh removal
and drainage. Cultures from the mesh grew C. krusei, and
histology showed fungal elements within the mesh (Fig. 2).
Blood cultures were repeatedly drawn throughout the patient’s
inpatient and outpatient course, but none was positive for yeast.
Following mesh removal, the patient was kept on micafungin for
10 days. Fungal susceptibility testing was not obtained and was
deemed unnecessary because C. krusei is generally considered
resistant to ﬂuconazole [6], has a lower susceptibility to
amphotericin B than other Candida species [7], and is susceptible
to echinocandin antifungals [8,9].
The patient slowly made a complete recovery and ﬁnally
resumed his normal activities. Nine months later, he underwent
closure of his ileostomy with an uneventful recovery.
Discussion
Infection with C. krusei, known for its resistance to ﬂucona-
zole [6], can occur in the susceptible host following manage-
ment or prophylaxis with ﬂuconazole [7]. Recent studies
showed improved survival with the use of new antifungals,
such as echinocandins [8,9].The patient we presented had multiple laparotomies, bowel
resections, and serious complications, including sepsis, fasciitis,
and wound infection. He received multiple antibacterials and
ﬂuconazole. Biologic mesh was used because it is theoretically
superior for contaminated wounds. Biologic mesh was ﬁrst
approved by the FDA in 1999 for use as an alternative to leaving
the abdomen open in contaminated abdominal wounds [10].
Studies have shown that this practice is usually successful [11,12].
Unlike synthetic mesh, biologic mesh can be from an animal
(porcine) or human source. The human dermis mesh is made from
an extracellular dermal matrix stripped from cells (acellular
dermal matrix). It provides a scaffold onto which the patient’s body
sends blood vessels, a process that leads to remodeling and also
allows blood supply and immunologic defenses; for this reason, it
is theoretically resistant to infection [13,14]. An important
drawback of biologic mesh, however, is its high cost [15]; the
cost of human-derived mesh is higher than that of animal mesh
[16]. Three recent reviews [17–19] have shed light on the issues of
hernia recurrence and mesh infection with the use of biologic
mesh. The data are insufﬁcient to draw any solid conclusions on
the infection risk of biologic mesh, and hernia recurrence is high.
In our case, the C. krusei infection persisted despite long-term
surgical drainage and management with micafungin. The secre-
tions of the wound tended to clear when the patient was receiving
the antifungal, and they re-accumulated when it was stopped, with
the repeat cultures growing the yeast. For this reason, a decision
was made to remove the biologic mesh. In summary, biologic mesh
can be used to close infected abdominal wounds. The case we
presented demonstrates that such a mesh can become chronically
infected with Candida spp. and thus require removal.
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